Compare MEHA & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEHA | OGEN |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.6M |
| IPO Year | N/A | N/A |
| Metric | MEHA | OGEN |
|---|---|---|
| Price | $0.19 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 852.3K | ★ 911.2K |
| Earning Date | 05-29-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,797,059.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.57 | N/A |
| 52 Week Low | $0.18 | $0.74 |
| 52 Week High | $8.00 | $18.90 |
| Indicator | MEHA | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.16 | 35.71 |
| Support Level | $0.18 | $0.77 |
| Resistance Level | $0.22 | $0.84 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 14.04 | 4.00 |
Functional Brands Inc operates in the nutraceutical supplement industry. It is a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, brain and memory, sleep, prenatal and urinary. It is focus on end-consumers through different channels that include pharmacies, wholesalers, international distributors and direct-to-consumers sales. The Company has two reportable segments: 1) Kirkman, which sells a range of nutraceuticals, supplements and related products direct to consumers; 2) HT Naturals, which sells a range of hemp products; and 3) Corporate, which generates no revenue. Key revenue is generated from Kirkman.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.